

## ETO (C-20): sc-9737

### BACKGROUND

ETO and ETO-2, which are alternatively designated MTG8 and MTG16, respectively, are members of the ETO transcription factor family. These transcription factors are characterized by a zinc-finger domain and four conserved domains, of which domain II is required for dimerization between family members. ETO and ETO-2 may function to mediate interactions between DNA binding proteins and transcriptional regulators, such as N-CoR. Frequently, the t(8;21) translocation of ETO produces the AML-1/ETO oncoprotein, which consists of the first 177 amino acids of AML-1 and all but the first 30 amino acids of ETO. AML-1/ETO expression is observed in 12-15% of acute myelogenous, M<sub>2</sub> subtype leukemias. The AML-1/ETO fusion proteins associate with multimeric N-CoR/mSin3/HDAC1 complexes, block differentiation and induce transcriptional repression by altering chromatin remodeling.

### CHROMOSOMAL LOCATION

Genetic locus: RUNX1T1 (human) mapping to 8q21.3; Runx1t1 (mouse) mapping to 4 A1.

### SOURCE

ETO (C-20) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the C-terminus of ETO of human origin.

### PRODUCT

Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin. Also available as TransCruz reagent for Gel Supershift and ChIP applications, sc-9737 X, 200 µg/0.1 ml.

Blocking peptide available for competition studies, sc-9737 P, (100 µg peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

### APPLICATIONS

ETO (C-20) is recommended for detection of ETO of mouse, rat and human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

ETO (C-20) is also recommended for detection of ETO in additional species, including equine, canine, porcine and avian.

Suitable for use as control antibody for ETO siRNA (h): sc-35342, ETO siRNA (m): sc-35343, ETO shRNA Plasmid (h): sc-35342-SH, ETO shRNA Plasmid (m): sc-35343-SH, ETO shRNA (h) Lentiviral Particles: sc-35342-V and ETO shRNA (m) Lentiviral Particles: sc-35343-V.

ETO (C-20) X TransCruz antibody is recommended for Gel Supershift and ChIP applications.

Molecular Weight of ETO: 70 kDa.

Positive Controls: MOLT-4 cell lysate: sc-2233, CCRF-CEM cell lysate: sc-2225 or CCRF-HSB-2 cell lysate: sc-2265.


### RESEARCH USE

For research use only, not for use in diagnostic procedures.

### STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

### DATA



ETO (C-20): sc-9737. Western blot analysis of ETO expression in AML-193 (A), CCRF-CEM (B), CCRF-HSB-2 (C), HL-60 (D), HuT 78 (E) and MOLT-4 (F) whole cell lysates.

### SELECT PRODUCT CITATIONS

- Zhang, J., et al. 2004. E protein silencing by the leukemogenic AML-1-ETO fusion protein. *Science* 305: 1286-1289.
- Lausen, J., et al. 2004. The nuclear receptor co-repressor (N-CoR) utilizes repression domains I and III for interaction and co-repression with ETO. *J. Biol. Chem.* 279: 49281-49288.
- Osman, D., et al. 2009. A *Drosophila* model identifies calpains as modulators of the human leukemogenic fusion protein AML1-ETO. *Proc. Natl. Acad. Sci. USA* 106: 12043-12048.
- Dunne, J., et al. 2010. AML1/ETO proteins control POU4F1/BRN3A expression and function in t(8;21) acute myeloid leukemia. *Cancer Res.* 70: 3985-3995.
- Khandanpour, C., et al. 2010. A variant allele of growth factor independence 1 (GFI1) is associated with acute myeloid leukemia. *Blood* 115: 2462-2472.
- Oakford, P.C., et al. 2010. Transcriptional and epigenetic regulation of the GM-CSF promoter by RUNX1. *Leuk. Res.* 34: 1203-1213.
- Fang, H.T., et al. 2012. Bortezomib interferes with C-KIT processing and transforms the t(8;21)-generated fusion proteins into tumor-suppressing fragments in leukemia cells. *Proc. Natl. Acad. Sci. USA* 109: 2521-2526.
- Zhen, T., et al. 2012. Targeting of AML1-ETO in t(8;21) leukemia by oridonin generates a tumor suppressor-like protein. *Sci. Transl. Med.* 4: 127ra38.

**MONOS**  
Satisfaction  
Guaranteed

Try **ETO (3H11): sc-134335**, our highly recommended monoclonal alternative to ETO (C-20).